CompletedNCT01626456

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Researchers compared ALKS 9072, Low and ALKS 9072, High, tracking side effects to assess long-term safety in people with schizophrenia.

Medication studyAges 18–70Multiple countries

The study in practice

Understand this study

Researchers compared ALKS 9072, Low and ALKS 9072, High, tracking side effects to assess long-term safety in people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations: Little Rock and 81 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateJune 2012

Recruitment status: Completed
Enrollment listed in the registry: 478
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Bulgaria, Malaysia, ...
Age range: From 18 Years to 70 Years
Official registry ID: NCT01626456
Official title: Show the full official title
A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia

Completed

Little Rock, United States · Springdale, United States · Garden Grove, United States

76 more locations

FAQ

What did researchers investigate?

Researchers compared ALKS 9072, Low and ALKS 9072, High, tracking side effects to assess long-term safety in people with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including ALKS 9072, Low and ALKS 9072, High.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.